Drug Discovery@nature.com 8 November 2013

Advertisement Reichert Life Sciences Surface Plasmon Resonance (SPR) Systems - Drug discovery instruments for real-time, label-free results  Reichert SPR systems generate precise kinetics (on/off rates), affinity and thermodynamics data for lead optimization. The ultra-sensitive systems are flexible and affordable. Read citations of Reichert systems in peer-reviewed abstracts.  ReichertSPR.com TABLE OF CONTENTS 8 November 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Choose Scientific Reports for fast, efficient, open access publishing  94% of authors said they are likely or very likely to recommend Scientific Reports to their colleagues* 91% of authors would publish in Scientific Reports again*  SUBMIT your paper today!  *Nature Publishing Group author survey, data correct as of September 2013   News Top Make or break for first splice-modulating agents doi:10.1038/nrd4151 If Duchenne muscular dystrophy drugs that modulate gene splicing can overcome key hurdles, they could boost enthusiasm for related antisense oligonucleotides in other indications. Full Text IL-17 antibodies gain momentum doi:10.1038/nrd4152 A Phase III trial for a first-in-class psoriasis drug provides encouraging data, but the emerging agents still have to prove their worth in a crowded autoimmune market. Full Text Trial watch: Success in amyloidosis trials supports potential of systemic RNAi doi:10.1038/nrd4165 Results from Phase I trials of Alnylam's antitransthyretin siRNA therapies indicate that these treatments safely and effectively reduce levels of transthyretin in healthy volunteers and in patients with transthyretin-related amyloidosis. Full Text Deal watch: Biogen and Amicus to pursue genetically validated Parkinson’s disease target doi:10.1038/nrd4166 Biogen Idec has teamed up with Amicus Therapeutics to develop a new approach to Parkinson’s disease based on targeting the lysosomal enzyme β-glucocerebrosidase. Full Text Analysis Top Building meditope-enabled mAbs doi:10.1038/scibx.2013.1178 Researchers have provided proof of concept for adapting the functionality of mAbs by modifying them with engineered peptides called meditopes. A company has been founded - Meditope Biosciences - to commercialize the technology. Full Text Advances in prostate cancer treatment doi:10.1038/nrd4068 This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer. Full Text Research Highlights Top Anticancer drugs: IDH2 drives cancer in vivo doi:10.1038/nrd4160 Two recent studies show that mutations in the metabolic gene isocitrate dehydrogenase 2 (IDH2) can drive the development of leukaemia and sarcoma in vivo. Full Text Neurodegenerative disorders: A PIR-fect storm doi:10.1038/nrd4159 This study shows that ‘immune receptors’ may have a role in Alzheimer’s disease and points to leukocyte immunoglobulin-like receptor B2 (LILRB2) as a potential therapeutic target for this disorder. Full Text Lysosomal storage diseases: Thioesterase mimetic reduces toxicity doi:10.1038/nrd4156 This study reports a small hydroxylamine derivative that delayed neurological deterioration and extended lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis (INCL) - a neurodegenerative lysosomal storage disease. Full Text Research & Reviews Top Metabolic targets for cancer therapy doi:10.1038/nrd4145 Here, the authors discuss the intimate relationship between metabolism and malignancy, focusing on therapeutic strategies and emerging agents targeting the metabolic rearrangements of cancer cells. Full Text Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain doi:10.1038/nrd3893 Glycine transporters are important regulators of the level of glycine, which can act as both an inhibitory neurotransmitter and a modulator of neuronal excitation. Here, the authors discuss the potential of glycine transporters as novel therapeutic targets for schizophrenia, alcohol dependence and pain. Full Text Immunological functions of the neuropilins and plexins as receptors for semaphorins doi:10.1038/nri3545 Semaphorins and their primary receptors, the neuropilins and plexins, participate in a wide range of innate and adaptive immune responses, which has implications for immune disorders such as multiple sclerosis, rheumatoid arthritis and allergy. Full Text Microbiota-mediated colonization resistance against intestinal pathogens doi:10.1038/nri3535 Colonization resistance - protection from exogenous pathogens by commensal bacteria - can be mediated by direct antagonism and by indirect effects on the host immune response. This Review outlines our current knowledge of immune-mediated colonization resistance against clinically relevant, antibiotic-resistant intestinal pathogens and how insights into commensal bacterial species and their mechanisms might be therapeutically used to restore resistance. Full Text Drug Discovery JOBS of the week Imaging of control drug release materials using hyperpolarised 129Xe MRI The University of Nottingham Postdoctoral Researcher in Biomaterials and Drug Delivery Vanderbilt University, Department of Chemical and Biomolecular Engineering Chemistry Faculty Position, Drug Discovery Department, Moffitt Cancer Center Moffitt Cancer Center Post-Doctoral Research Fellow, Drug Discovery Fred Hutchinson Cancer Research Center Medical Director, Global Drug Safety Product Leader (m / f) Merck Group More Science jobs from Drug Discovery EVENT Oncology imaging for drug development 12.03.14 London, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.